NKGen Biotech (NASDAQ:NKGN) mentioned it has dosed its first affected person in a Part 1/2a research of its cell remedy SNK01 within the therapy of average Alzheimer’s illness, AD.
The biotech firm mentioned the Part 1 portion of the research will assist decide the utmost tolerated and/or really helpful dose for the Part 2 portion, which shall be a randomized double-blind trial evaluating the security and efficacy of the therapy in AD.
NKGen mentioned the primary affected person acquired a dose of 6 billion cells, 50% greater than the utmost dose in a previous Part 1 research. The company said it hopes the elevated dose will present “even larger cognitive profit and larger results in protein and neuroinflammation ranges.
The corporate plans to conduct an interim knowledge readout from the research in Q3 2024.
NKGen went public by way of a SPAC merger with Graf Acquisition Corp. IV earlier this yr.
NKGen Biotech (NASDAQ:NKGN) mentioned it has dosed its first affected person in a Part 1/2a research of its cell remedy SNK01 within the therapy of average Alzheimer’s illness, AD.
The biotech firm mentioned the Part 1 portion of the research will assist decide the utmost tolerated and/or really helpful dose for the Part 2 portion, which shall be a randomized double-blind trial evaluating the security and efficacy of the therapy in AD.
NKGen mentioned the primary affected person acquired a dose of 6 billion cells, 50% greater than the utmost dose in a previous Part 1 research. The company said it hopes the elevated dose will present “even larger cognitive profit and larger results in protein and neuroinflammation ranges.
The corporate plans to conduct an interim knowledge readout from the research in Q3 2024.
NKGen went public by way of a SPAC merger with Graf Acquisition Corp. IV earlier this yr.